Shares of Guardant Health Inc. (GH) skyrocketed 21.77% in after-hours trading on Wednesday, following the release of the company's exceptional third-quarter financial results that significantly outperformed analyst expectations. The precision oncology company demonstrated robust growth and improved financial performance across key metrics, sparking investor enthusiasm.

Guardant Health reported Q3 revenue of $265.2 million, marking a substantial 39% year-over-year increase and handily beating the analyst consensus estimate of $235.7 million. The company's adjusted earnings per share (EPS) came in at -$0.39, significantly better than the expected -$0.76. Additionally, adjusted EBITDA loss narrowed to $45.5 million, outperforming the estimated loss of $54.7 million.

The strong quarterly performance was driven by impressive growth in oncology test volume, which increased by 40% compared to the previous year. Notably, the company's Shield screening tests generated $24.1 million in revenue, up from just $1 million in the prior year period, indicating rapid adoption of its cancer screening technology. In light of these results, Guardant Health raised its full-year 2025 revenue guidance to $965-$970 million, up from the previous forecast of $915-$925 million. This upward revision, coupled with the company's strategic collaborations to expand Shield access nationwide, has significantly boosted investor confidence in Guardant Health's growth trajectory and market position in the competitive precision oncology sector.